| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080551 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(5 months ago) | |
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | GILEAD SCIENCES INC | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 1 month ago) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US8841310 | GILEAD SCIENCES INC | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Dec, 2025
(2 years from now) | |
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(9 years from now) | |
Complera is owned by Gilead Sciences Inc.
Complera contains Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate.
Complera has a total of 9 drug patents out of which 2 drug patents have expired.
Expired drug patents of Complera are:
- US8101629
- US8080551
Complera was authorised for market use on 10 August, 2011.
Complera is available in tablet;oral dosage forms.
Complera can be used as treatment of hiv infection.
The generics of Complera are possible to be released after 14 January, 2033.
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
COMPLERA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic